Andrea van Elsas

Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen

S. H. van der Burg, P. Schrier, A. van Elsas, 1996, European journal of immunology.

Target validation in silico: does the virtual patient cure the pharma pipeline?

Ton Rullmann, Wynand Alkema, W. Alkema, 2006, Expert opinion on therapeutic targets.

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

J. Allison, A. van Elsas, A. Hurwitz, 1999, The Journal of experimental medicine.